Ipamorelin/CJC-1295 mix 5 mg + 5 mg Product Information
Ipamorelin / CJC 1295 Blend 10 mg (5 mg + 5 mg) research-grade lyophilized peptide powder in a glass vial. This blend combines the selective ghrelin receptor agonist Ipamorelin with CJC-1295 (no DAC, Mod GRF 1-29), a Growth Hormone Releasing Hormone (GHRH) analog, studied in experimental models of pituitary function and growth hormone (GH) secretion dynamics. Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use. Purity High-purity research grade Form Lyophilized peptide powder Content 5 mg Ipamorelin & 5 mg CJC-1295 (no DAC) per vial Packaging Glass vial with sterile closure Storage Store lyophilized at 2–8 °C (desiccated, protect from light) Molecular formula Mixture Molecular weight Mixture Sequences Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 CJC-1295 (no DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 CAS numbers 170851-70-4 (Ipamorelin) 863288-34-0 (CJC-1295 no DAC) In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see Bacteriostatic water – 10 ml . Research Overview The Ipamorelin / CJC-1295 (no DAC) Blend 10 mg (5 mg + 5 mg) combines two complementary growth hormone secretagogues: Ipamorelin, a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R), and CJC-1295 (no DAC), a modified GHRH analog (Mod GRF 1-29). In experimental endocrinology, this dual-agonist blend is used as a tool compound to investigate GH/IGF-1 axis regulation, pituitary signaling and pulsatile growth hormone secretion patterns in in vitro and in vivo research models. Primary Research Areas Growth hormone secretion dynamics: Laboratory models exploring synergistic GH release via concurrent activation of GHS-R by Ipamorelin and GHRH receptors by CJC-1295 (no DAC), including studies of GH pulse amplitude and frequency. Pituitary and hypothalamic signaling: Experiments evaluating downstream intracellular pathways in pituitary somatotrophs and hypothalamic circuits in response to combined ghrelin receptor and GHRH receptor stimulation. GH/IGF-1 axis modulation: Preclinical research assessing how the blend influences growth hormone and insulin-like growth factor 1 (IGF-1) patterns in controlled endocrine models, without implying any therapeutic or performance outcomes. Endocrine feedback and receptor interactions: Studies focused on feedback regulation, receptor desensitization and cross-talk between ghrelin, GHRH and somatostatin pathways under dual-secretagogue stimulation. Method development and assay calibration: Use of the Ipamorelin / CJC-1295 blend as a reference tool in assay development, bioanalytical method validation and mechanistic GH secretion research in vitro and in vivo.
